Filovirus hemorrhagic fever outbreak case management: A review of current and future treatment options

Journal of Infectious Diseases

Volumn 204, Issue SUPPL. 3, 2011, Pages

  Roddy, Paul ^a   Colebunders, Robert ^b,c   Jeffs, Benjamin ^a   Palma, Pedro Pablo ^a   Van Herp, Michel ^d   Borchert, Matthias ^e  

^a MÉDECINS SANS FRONTIÈRES   (Switzerland)

^b INSTITUTE OF TROPICAL MEDICINE   (Belgium)

^c UNIVERSITY OF ANTWERP   (Belgium)

^d MÉDECINS SANS FRONTIÈRES   (Belgium)

^e CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE PHOSPHORODIAMIDATE MORPHOLINO OLIGOMER; DROTRECOGIN; MORPHOLINE DERIVATIVE; OLIGOMER; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

CASE MANAGEMENT; COMMUNITY; COMMUNITY RESISTANCE; DISSEMINATED INTRAVASCULAR CLOTTING; EPIDEMIC; FILOVIRUS HEMORRHAGIC FEVER; FILOVIRUS INFECTION; HEALTH CARE PERSONNEL; HUMAN; INFECTION CONTROL; MARBURG HEMORRHAGIC FEVER; MEDICAL RECORD; NONHUMAN; OCCUPATIONAL EXPOSURE; PATIENT CARE; POST EXPOSURE PROPHYLAXIS; PRIORITY JOURNAL; REVIEW; SEPSIS; SUPPORTIVE TREATMENT; TREATMENT REFUSAL; VIRUS HEMORRHAGIC FEVER; VIRUS INFECTION; VIRUS INHIBITION; VIRUS REPLICATION; ZAIRE EBOLAVIRUS INFECTION;

ANTIVIRAL AGENTS; DISEASE OUTBREAKS; FILOVIRIDAE; FILOVIRIDAE INFECTIONS; HUMANS; VIRUS REPLICATION;

EID: 80054761746     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/jir297     Document Type: Review

References (45)

1. Feldmann H, Geisbert TW, Jahrling PB, et al. In: Filoviridae. Virus taxonomy, VIIIth report of the ICTV. London: Elsevier/Academic Press, 2004; 645-53.
2. WHO, CDC. Infection control for viral haemorrhagic fevers in the African health care setting. Geneva: WHO, 1998. publications/ebola/WHO-EMC-ESR-98-2-EN/ en/. Accessed 31 October 2010.
3. Bausch DG, Sprecher AG, Jeffs B, Boumandouki P. Treatment of Marburg and Ebola hemorrhagic fevers: a strategy for testing new drugs and vaccines under outbreak conditions. Antiviral Res 2008; 78:150-61.
4. WHO. Case of Marburg haemorrhagic fever imported into the Netherlands from Uganda. Geneva: WHO, 2008. http://www.who.int/csr/ don/2008-07-10/en/index. html. Accessed 31 October 2010.
5. WHO. Ebola haemorrhagic fever in the Democratic Republic of the Congo. Geneva: WHO, 2008. .
6. CDC. Imported case of Marburg hemorrhagic fever-Colorado, 2008. Morbidity and Mortality Weekly Report 2009; 58:1377-81.
7. Kuhn JH. Filoviruses: a compendium of 40 years of epidemiological, clinical, and laboratory studies. Wien: Springer. 2008; 411.
8. Geisbert TW, Hensley LE, Geisbert JB, et al. Postexposure treatment of Marburg virus infection. Emerg Infect Dis 2010; 7:1119-22.
9. Warren TK, Warfield KL, Wells J, et al. Advanced antisense therapies for postexposure protection against lethal filovirus infections. Nat Med 2010; 16:991-4.
10. Geisbert TW, Lee ACH, Robbins M, et al. Postexposure protection of nonhuman primates against a lethal Ebola virus challenge with RNA interference: a proof-of-concept study. Lancet 2010; 375:1896-905.
11. Bray M, Murphy FA. Filovirus research: knowledge expands to meet a growing threat. J Infect Dis 2007; 196(Suppl 2):S438-S443. (Pubitemid 351417292)
12. Feldman H. Are we any closer to combating Ebola infections? Lancet 2010; 375:1850-2.
13. Mahanty S, Bray M. Pathogenesis of filoviral haemorrhagic fevers. Lancet Infect Dis 2004; 4:487-98. (Pubitemid 39077918)
14. Bernard GR, Vincent JL, Laterre PF, et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. New Engl J Med 2001; 344:699-709. (Pubitemid 32204987)
15. Hensley LE, Stevens EL, Yan SB, et al. Recombinant human activated protein C for the postexposure treatment of Ebola hemorrhagic fever. J Infect Dis 2007; 196(Suppl 2):S390-S399. (Pubitemid 351417286)
16. Geisbert TW, Young HA, Jahrling PB, et al. Mechanisms underlying coagulation abnormalities in Ebola hemorrhagic fever: overexpression of tissue factor in primate monocytes/macrophages is a key event. J Infect Dis 2003; 188:1618-29. (Pubitemid 38010671)
17. Geisbert TW, Daddario-DiCaprio KM, Geisbert JB, et al. Marburg virus Angola infection of Rhesus macaques: pathogenesis and treatment with recombinant nematode anticoagulant protein c2. J Infect Dis 2007; 196:S372-S381. (Pubitemid 351417284)
18. Warfield KL, Swenson DL, Olinger GG, et al. Gene-specific countermeasures against Ebola virus based on antisense phosphorodiamidate morpholino oligomers. PLoS Pathog 2006; 2:e1.
19. Enterlein S, Warfield KL, Swenson DL, et al. VP35 knockdown inhibits Ebola virus amplification and protects against lethal infection in mice. Antimicrob Agents Chemother 2006; 50:984-93. (Pubitemid 43327804)
20. Swenson DL, Warfield KL, Warren TK, et al. Chemical modifications of antisense morpholino oligomers enhance their efficacy against Ebola virus infection. Antimicrob Agents Chemother 2009; 53:2089-99.
21. Spurgers KB, Sharkey CM, Warfield KL, Bavari S. Oligonucleotide antiviral therapeutics: antisense and RNA interference for highly pathogenic RNA viruses. Antiviral Res 2008; 78:26-36.
22. Feldmann H, Jones SM, Daddario-DiCaprio KM, et al. Effective postexposure treatment of Ebola infection. PLoS Pathog 2007; 3:e2.
23. Geisbert TW, Hensley LE, Jahrling PB, et al. Treatment of Ebola virus infection with a recombinant inhibitor of factor VIIa/tissue factor: a study in rhesus monkeys. Lancet 2003; 362:1953-8. (Pubitemid 37548417)
24. Sanchez A, Geisbert TW, Feldmann H. Marburg and Ebola viruses. In: Knipe DM, Howley PM, et al., eds. Fields virology. Philadelphia: Wolters Kluwer/Lippincott Williams and Wilkins, 2007; 1409-48.
25. International Society for Infectious Diseases. Ebola, lab accident death-Russia (Siberia) [cited 2004 May 22]. . promedmail.org/pls/apex/f?p=2400: 1202:2327768761862507::NO::F2400- P1202-CHECK-DISPLAY,F2400-P1202-PUB-MAIL-ID:X, 25465. Accessed 31 October 2010.
26. Kortepeter MG, Martin JW, Rusnak JM, et al. Managing potential laboratory exposure to Ebola virus by using a patient biocontainment care unit. Emerg Infect Dis 2008; 14:881-7DOI: 10.3201/eid1406.071489.
27. Ndambi R, Akamituna P, Bonnet MJ, Tukadila AM, Muyembe- Tamfum JJ, Colebunders R. Epidemiologic and clinical aspects of the Ebola virus epidemic in Mosango, Democratic Republic of the Congo, 1995. J Infect Dis 1999; 179(Suppl 1):S8-S10. (Pubitemid 29091374)
28. Baert B. Ebola outbreak preparedness & management. Brussels, Belgium: Médecins Sans Frontières Belgium, 2001; 1-124[Internal Médecins Sans Frontières guideline available on request from corresponding author].
29. Sterk E. Filovirus haemorrhagic fever guideline. Barcelona: Médecins Sans Frontières Operational Center Barcelona - Athens, 2008; 1-138[Internal Médecins Sans Frontières guideline available on request from corresponding author].
30. Jeffs B, Roddy P, Weatherill D, et al. The Médecins Sans Frontières intervention in the Marburg hemorrhagic fever epidemic, Uige/ Angola, 2005. I. Lessons learned in the hospital. J Infect Dis 2007; 196 (Suppl 2):S154-S161.
31. Bausch DG, Feldmann H, Geisbert TW, et al. Outbreaks of filovirus hemorrhagic fever: time to refocus on the patient. J Infect Dis 2007; 196(Suppl 2):S136-S141. (Pubitemid 351417252)
32. Casillas A, Nyamathi A, Sosa A, Wilder CL, Sands H. A current review of Ebola virus: pathogenesis, clinical presentation, and diagnostic assessment. Biol Res Nurs 2003; 4:268-75.
33. Hewlett BS, Amola RP. Cultural contexts of Ebola in Northern Uganda. Emerg Infect Dis 2003; 9:1242-8. (Pubitemid 37210563)
34. Larkin M. Ebola outbreak in the news. Lancet Infect Dis 2003; 3: 255.
35. Formenty P, Libama F, Epelboin A, et al. L'épidémie de fièvre hémorragique a virus Ebola en République du Congo, 2003: une nouvelle stratégie? Médecine Tropicale 2003; 63:291-5. (Pubitemid 46417000)
36. WHO. Outbreak(s) of Ebola haemorrhagic fever, Congo and Gabon, October 2001-July 2002. Wkly Epidemiol Rec 2003; 78:223-8.
37. Hewlett BS, Epelboin A, Hewlett BL, Formenty P. Medical anthropology and Ebola in Congo: cultural models and humanistic care. Bull Soc Pathol Exot 2005; 98:230-6. (Pubitemid 41500865)
38. Roddy P, Weatherill D, Jeffs B, et al. The Médecins Sans Frontières intervention in the Marburg hemorrhagic fever epidemic, Uige, Angola, 2005. II. Lessons learned in the community. J Infect Dis 2007; 196(Suppl 2):S162-7. (Pubitemid 351417256)
39. Raabe V, Mutyaba I, Roddy P, et al. Infection control during filoviral hemorrhagic fever outbreaks: preferences of community members and health workers in Masindi, Uganda. Trans R Soc Trop Med Hyg 2010; 104:48-50.
40. Tadesse M, Tadesse T. Epidemiology of needlestick injuries among health-care workers in Awassa City, Southern Ethiopia. Trop Doct 2010; 40:111-3.
41. Colebunders R, Sleurs H, Pirard P, et al. Organisation of health care during an outbreak of Marburg haemorrhagic fever in the Democratic Republic of Congo, 1999. J Infect Dis 2004; 48:347-53. (Pubitemid 38519290)
42. Mupapa K, Massamba M, Kibadi K, et al. Treatment of Ebola hemorrhagic fever with blood transfusions from convalescent patients. J Infect Dis 1999; 179(Suppl 1):S118-S123.
43. Dellinger RP, Levy MM, Carlet JM, et al. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008. Crit Care Med 2008; 36:296-327.
44. Colebunders R, Tshomba A, Van Kerkhove M, et al. Marburg hemorrhagic fever in Durba and Watsa, Democratic Republic of the Congo: clinical documentation, features of illness, and treatment. J Infect Dis 2007; 196(Suppl 2):S148-S153. (Pubitemid 351417254)
45. Buhler S. Health care workers' experiences and preferences regarding documentation of clinical data and its transference from Ebola and Marburg wards [MSc thesis]. London: London School of Hygiene and Tropical Medicine, 2008. [Thesis available on request from corresponding author.] Review